|Institutional Source||Beutler Lab|
|Gene Name||tumor necrosis factor (ligand) superfamily, member 8|
|Synonyms||CD153, CD30LG, Cd30L|
|Is this an essential gene?||Non essential (E-score: 0.000)|
|Stock #||R4154 (G1)|
|Chromosomal Location||63831308-63861347 bp(-) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to G at 63834358 bp|
|Amino Acid Change||Serine to Proline at position 157 (S157P)|
|Ref Sequence||ENSEMBL: ENSMUSP00000030047 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000030047]|
|Predicted Effect||probably benign
AA Change: S157P
PolyPhen 2 Score 0.002 (Sensitivity: 0.99; Specificity: 0.30)
AA Change: S157P
|Meta Mutation Damage Score||0.0898|
|Coding Region Coverage||
|Validation Efficiency||98% (51/52)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF8/CD30, which is a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. The engagement of this cytokine expressed on B cell surface plays an inhibitory role in modulating Ig class switch. This cytokine was shown to enhance cell proliferation of some lymphoma cell lines, while to induce cell death and reduce cell proliferation of other lymphoma cell lines. The pleiotropic biologic activities of this cytokine on different CD30+ lymphoma cell lines may play a pathophysiologic role in Hodgkin's and some non-Hodgkin's lymphomas. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2011]
PHENOTYPE: Homozygous null mice diplay decreased susceptibility to graft versus host disease. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Tnfsf8||
(F):5'- TATCCACCCTGACTGATATGGTAG -3'
(R):5'- TACCCTTCTAGAAAACAGAGATGC -3'
(F):5'- ACCCTGACTGATATGGTAGAGTTGAC -3'
(R):5'- AGAGGTTTCCAAGATGTACCTAAC -3'